BETA-ADRENOBLOCKERS IN LONG-TERM MONOTHERAPY AMONG PATIENTS WITH ARTERIAL HYPERTENSION: EFFECTS ON QUALITY OF LIFE AND TREATMENT COMPLIANCE
Abstract
Treatment compliance and quality of life (QoL) in long-term monotherapy with various beta-adrenoblockers, BAB (propranolol, metoprolol, nadolol, atenolol, bisoprolol, and nebivolol) were compared in 130 men with arterial hypertension (AH), aged 30-59 years. Treatment compliance was assessed using the Morisky-Green test, and QoL – the General Well Being Questionnaire (GWBQ). Together with good antihypertensive effectiveness, tolerability, and low incidence of adverse effects, nebivolol demonstrated the best treatment compliance and QoL improvement, compared to the other BAB. The lowest treatment compliance and minimal QoL improvement were observed in patients receiving propranolol. Therefore, in long-term BAB monotherapy among AH patients, nebivolol is a medication of choice, due to high treatment compliance and positive effects on QoL (in particular, on sexual function in men).
About the Author
F. Z. Kasumova
Азербайджанский государственный институт усовершенствования врачей имени А.Алиева, кафедра внутренних болезней II, Баку
Russian Federation
Russian Federation
References
1. Конради А.О., Полуничева Е.В. Недостаточная приверженность к лечению артериальной гипертензии: причины и пути коррекции // Артериальная гипертензия, 2004; 3 (Т10): 2-7.
2. Марцевич С.Ю. β-адреноблокаторы. Принцип терапии в свете международных рекомендаций // Кардиоваскулярная терапия и профилактика. 2005; 4(4): 4-9.
3. Небилет (небиволол) – третье поколение блокаторов β-адренорецепторов. Дайджест. Украинск. Медичний raconuc 2000; 1 (15): 45-48.
4. Kearney P.M, Wbelton M., Reynolds K. et al. Worldwide prevalence of hypertension: a systematic review//J. Hypertens 2004; 22(1):11=19
5. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of self-reported measure of medical adherence // Med.Care, 1986; 24: 67-73.
6. Haiiar J., Kotcben TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000 // JAMA 2003; 290 (2); 199-206.
7. Hosic J., Wiklind J. Managing hypertension in general practice: can we do better? // J. Human Hypertension, 1995; 9: S15-S18.
8. Jansen P.M. Zeitz. O., Hasenfuss G.Y. Trans and sustained impacts of hydroxyl radical on sarcoplasmic reticulum function: protective effects of nebivolol // Eur. J.Pharm.col. 1999; 366(2- 3):223-232.
9. Siegrist J., Jungle A. Conceptual and methodologist problem in research on the quality of life in clinical medicine // Soc. Sci. Med 1989; 29(3):46.
10. Siegrist J., Junge A., Funfstuck G. // Med.Welt – 1991, Bd 42 – S.133-138.
11. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients // Blood pressure, 2001; 10: 62-73.
12. Waeber B., Burnier V., Brunner H.R. How to improve adherence with prescribed treatment in hypertensive patients // J.Cardiovasc. Pharmacol, 2000; 36 (suppl – 3): S23-S26.
Review
For citations:
Kasumova F.Z. BETA-ADRENOBLOCKERS IN LONG-TERM MONOTHERAPY AMONG PATIENTS WITH ARTERIAL HYPERTENSION: EFFECTS ON QUALITY OF LIFE AND TREATMENT COMPLIANCE. Russian Journal of Cardiology. 2010;(5):52-56. (In Russ.)
Views:
475
Email this article 